Where do the molecular targets come from?
Cancer is caused by abnormal changes in a person’s genes that can cause cancer cells to multiply and grow. These gene abnormalities are known as molecular targets. They may be acquired or inherited.
Learn more about:
- What are genes?
- Acquired gene changes
- Inherited faulty genes
- Are Medicare rebates available for genetic tests?
Listen to a podcast on New Treatments – Immunotherapy and Targeted Therapy
Genes are made up of DNA (deoxyribonucleic acid). They are found in every cell of the body and are inherited from both parents. Each human cell has about 20,000 genes. Genes tell the cell what to do, and when to grow and divide. Cells use this information to make proteins that carry out specific functions in the body.
Most cancers are not caused by inherited genetic changes but by mistakes that build up over time in the body’s cells (known as acquired changes). These gene faults are in the structure of the cancerous cell, not in normal cells.
Researchers have found several gene abnormalities that play a key role in a number of cancers. For example:
- epidermal growth factor receptor (EGFR) mutations in lung cancer
- BRAF mutations in melanoma, bowel and thyroid cancers
- anaplastic lymphoma kinase (ALK) mutations in lung cancer and neuroblastoma
- KRAS mutations in bowel cancer
- NRAS mutations in melanoma, leukaemia and bowel cancer
- high levels of human epidermal growth factor receptor 2 (HER2) in breast and stomach cancers
- KIT mutations in gastrointestinal stromal tumours and melanoma.
To find out if the cancer contains a change in a gene or related protein that may respond to a particular targeted therapy drug, your doctor will take a tissue sample from the cancer and send it to a laboratory for molecular testing. It may take from a few days to a few weeks before you receive the results.
Some genetic abnormalities are linked to a faulty gene (mutation) we inherit from our parents. Inherited faulty genes may increase a person’s risk of developing cancer. However, not all people who inherit a faulty gene develop cancer.
About 5% of cancers are caused by an inherited faulty gene. Inherited genetic conditions associated with cancer continue to be discovered, for example:
- an inherited mutation in one of the BRCA genes is linked to breast, ovarian and prostate cancers
- Lynch syndrome increases the risk of developing bowel, uterine, ovarian and stomach cancers
- Li-Fraumeni syndrome increases the risk of developing breast, primary bone and adrenal cancers
- Cowden syndrome increases the risk of developing breast, thyroid and uterine cancers
- familial adenomatous polyposis (FAP) is a risk factor for bowel, stomach and thyroid
If your doctor suspects that the cancer is linked to an inherited gene fault, they will refer you to a family cancer service or genetic counsellor. A pathologist can run special tests on a blood or tissue sample to look for possible inherited gene changes. This is known as a genetic test.
Knowing whether you have a particular faulty gene may help determine suitable treatment options. Doctors may be able to recommend a targeted therapy drug that has been shown to work on cancers caused by that faulty gene.
If you are concerned about your family risk factors, talk to your doctor about having regular check-ups or ask for a referral to a family cancer clinic. To find out more, call Cancer Council 13 11 20.
|Medicare rebates are available for genetic tests for some people with specific cancers. You may need to meet certain eligibility requirements to have a Medicare-funded test. For more information about genetic testing, talk to your specialist or family cancer clinic, or call 13 11 20. Visit genetics.edu.au to find a family cancer clinic near you.|
This information was reviewed by: Dr Fiona Day, Medical Oncologist, Calvary Mater Newcastle, and Conjoint Senior Lecturer, University of Newcastle, NSW; Dawn Bed , 13 11 20 Consultant, Cancer Council Queensland; Jennifer Cardwell, Consumer; Christine Henneker, Nurse Practitioner Cancer Services, WA Country Health Service, WA; Dr Rohit Joshi, Medical Oncology Consultant, Calvary Central Districts Hospital, and Clinical Lecturer, University of Adelaide, SA; Prof Ross McKinnon, Director, Flinders Centre for Innovation in Cancer, SA; Prof Miles Prince, Haematologist, Director of Molecular Oncology and Cancer Immunology, Epworth HealthCare, VIC; Prof Ben Solomon, Medical Oncologist, and Group Leader, Molecular Therapeutics and Biomarkers Laboratory, Peter MacCallum Cancer Centre, VIC; Dr Subotheni Thavaneswaran, Medical Oncologist, The Kinghorn Cancer Centre and St Vincent’s Hospital, and Translational Research Fellow, Garvan Institute of Medical Research, NSW; A/Pro Kathy Tucker, Clinical Cancer Geneticist, Nelune Comprehensive Cancer Centre, NSW.
View the Cancer Council NSW editorial policy.
The information on this page is also available for download.
Targeted therapy is a type of drug treatment that attacks specific features of cancer cells, known as molecular targets, to stop the cancer growing and spreading. Other names for targeted therapy include biological therapies and molecular targeted therapy.